Were the interests of the vulnerable truly served? the predictable failure of HIVIG

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages

  Ammann, Arthur J ^a   Gough, Kerry ^a   Caplan, Arthur ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; DRUG COST; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PREGNANT WOMAN; PRIORITY JOURNAL; UGANDA; VIRUS LOAD; VIRUS TRANSMISSION;

FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY;

EID: 84865766335     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318253a5dc     Document Type: Letter

References (19)

1. Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr. 2011;58:399-407.
2. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis. 1999;179:567-575.
3. Stiehm ER, Fletcher CV, Mofenson LM, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000;181:548-554.
4. Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993;168:298-305.
5. Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group. Blood. 1994;84: 2130-2135.
6. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA. 1995;92:1195-1199.
7. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009-4018.
8. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999;10:431-438.
9. Binley JM, Clas B, Gettie A, et al. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology. 2000;270: 237-249.
10. Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis. 1997;175:283-291.
11. Takada A, Feldmann H, Ksiazek TG, et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77:7539-7544.
12. Cummins LM, Weinhold KJ, Matthews TJ, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood. 1991;77:1111-1117.
13. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA. 2011;108:11181-11186.
14. Homsy J, Meyer M, Tateno M, et al. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science. 1989;244:1357-1360.
15. Vigano A, Bricalli D, Trabattoni D, et al. Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Hum Retroviruses. 1998;14:727-34.
16. Willey S, Aasa-Chapman MM, O'Farrell S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology. 2011;8:16.
17. Mofenson LM. Prevention of mother-to-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr. 2011;58:359-362.
18. Caplan AL. Clinical trials of drugs and vaccines among the desperately poor in poor nations: ethical challenges and ethical solutions. Clin Pharmacol Ther. 2010;88:583-584.
19. Presidential Commission for the Study of Bioethical Issues. Moral science: protecting participants in human subjects research. 21012. 2011. Available at: http://bioethics.gov/cms/node/558. Accessed March 27, 2012.